DNA vaccine adjuvant using Micro RNA-155 and construction method thereof

A nucleic acid vaccine and construction method technology, applied in the fields of medical biology and immune activity enhancement of nucleic acid vaccines, can solve problems such as research reports on vaccine adjuvants that do not use MicroRNA-155 plasmid vector
CN101972476AInactive Publication Date: 2011-02-16SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
1 Cites 6 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Publication Date
2011-02-16
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to the technical field of medical biology. Micro RNA-155 is micro ribonucleic acid (RNA) for regulating the maturation and natural immunoreaction of T cells and B cells. The invention provides a micro RNA-155-based plasmid for enhancing the immune effect of deoxyribonucleic acid (DNA) vaccine cells. A plasmid pcDNA 3.1-pre-miR-155 is obtained by inserting an expression sequence of a micro RNA-155 precursor molecule into a pcDNA-3.1 plasmid, and the micro RNA-155 precursor molecules can be expressed efficiently without influencing the expression capability of the co-transfected DNA vaccine. In an in-vivo test, the plasmid and the DNA vaccine are injected at the same time and have the capability of effectively introducing cellular immunoreaction, and such capability isrepresented by the increase of antigenically specific spleen IFN-gamma positive cells and enhancement of target killing capability of spleen CD8 positive cells. The plasmid of the invention can be added into the conventional DNA vaccine preparation and injected together so as to obviously promote the cellular immunoreaction induced by the DNA vaccine, and serves as a novel cell immune adjuvant.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the technical field of medical biology, in particular to the technical field of enhancing the immune activity of nucleic acid vaccines. Background technique

[0002] MicroRNAs are abundant endogenous non-coding RNAs that regulate the expression of targeted mRNAs through defective base pairing in the 3′UTR region during transcription, thereby regulating mRNA cleavage and transcriptional repression. (Kato, M. and Slack, F.J. (2008) microRNAs: small molecules with big roles-C.elegans to human cancer. Biol. Cell, 100, 71-81.) MicroRNAs mainly regulate many biological processes, including innate immune response differentiation and activation of many cells in the (Garzon, R. and Croce, C.M. (2008) MicroRNAs in normal and malignant hematopoiesis. Curr. Opin. Hematol., 15, 352-358.) One of the typical MicroRNAs: MicroRNA-155 is a regulatory T cell and Small RNAs for B cell maturation and innate immune responses. (Rodriguez, A., Vigo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More